BetaShares Global Green Bond Currency Hedged ETF logo

BetaShares Global Green Bond Currency Hedged ETF (GBND)

Market Closed
ASX ASX
- Market Cap
- Div Yield
4,822 Volume
Want to track GBND and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

GBND pays dividends to its shareholders, with the most recent payment made on Jan 19, 2026.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on ASX (AUD).

BetaShares Global Green Bond Currency Hedged ETF (GBND) FAQ

On which exchange is it traded?

BetaShares Global Green Bond Currency Hedged ETF is listed on ASX.

What is its stock symbol?

The ticker symbol is GBND.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has BetaShares Global Green Bond Currency Hedged ETF ever had a stock split?

No, there has never been a stock split.

BetaShares Global Green Bond Currency Hedged ETF Profile

ASX Exchange
DE Country

Overview

Genomtec S.A is at the forefront of molecular diagnostics, focusing on the research, development, manufacturing, and commercialization of cutting-edge products within the realm of optical systems and isothermal nucleic acid amplification methods. With a reach that extends beyond its base in Wroclaw, Poland to the global market, the company stands out for its commitment to delivering mobile genetic diagnosis solutions. Since its inception in 2016, Genomtec has been dedicated to enhancing patient care by making diagnostic processes more efficient through technological innovations. Its operations are geared towards making the detection of viruses, bacteria, fungi, and genetic mutations both accessible and reliable for a wide range of patients by analyzing various biological samples.

Products and Services

  • Genomtec ID:

    A cornerstone of Genomtec’s offerings, the Genomtec ID is a device designed to transform the landscape of genetic diagnosis. Utilizing the innovative Streamlined Nucleic Acid Amplification Technology (SNAAT), it enables the rapid identification of viruses, bacteria, fungi, and genetic mutations. This technology is particularly adept at analyzing a wide variety of biological materials including swabs, urine, saliva, blood, and other body fluids, facilitating mobile and efficient diagnostics directly at the point of care.

  • Genomtec Tumor:

    Targeting the critical field of oncology, Genomtec Tumor leverages SNAAT to identify neoplastic mutations and mutations with prognostic value in cancers. This approach not only aids in the early detection of cancerous mutations but also provides valuable prognostic information, which can be crucial in tailoring individual treatment plans for patients with neoplastic diseases.

  • Genomtec SARS-CoV-2 EvaGreen and Direct-RT-LAMP CE-IVD Kit:

    In response to the global COVID-19 pandemic, Genomtec developed this specialized kit to detect SARS-CoV-2 RNA in various biological samples from patients suspected of having COVID-19. The kit’s significance lies in its ability to facilitate swift and reliable diagnostics, which is crucial for effective disease management and containment strategies.

  • Genomtec RT-LAMP CE-IVD Duo-Kit:

    This product represents Genomtec's solution to the evolving challenge of detecting all variants of the SARS-CoV-2 virus. It underscores the company’s adaptability and commitment to combating the pandemic by providing a diagnostic tool that can keep pace with the virus's mutations. This ensures that healthcare providers have access to accurate and up-to-date diagnostic capabilities.

Contact Information

Address: Bierutowska Street 57-59, Wroclaw, Poland, 51-317
Phone: 48 793 440 931